**Supplementary File**

The immunogenetics of viral antigen response is associated with sub-type specific glioma risk and survival

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Table S1: GWAS glioma meta results by subtype for the GRS variants**

[Link to Box Excel Worksheet](https://ucsf.box.com/s/v2sklvl682f8f8hokzgvh8lzhb7ow9o0)

All SNPs that were included in each GRS, basic variant information and beta/SE/p-value for a meta-GWAS for the association of the SNPs on each glioma subtype.

**Table S2: SNP2HLA HLA variant glioma risk results by subtype**

[Link to Box Excel Worksheet](https://ucsf.box.com/s/yusu84xwun539prce7gm7vlowgm027vy)

All HLA alleles/genes which were imputed via SNP2HLA, beta/SE/p-value for associations in a meta-analysis of risk analysis of each of the HLA alleles on each glioma subtype.

**Table S3: Summary of GRS-glioma risk significant results\***

|  |  |  |  |
| --- | --- | --- | --- |
| **Subtype** | **Antigen GRS** | **Meta OR (95% CI)** | **Meta P-value** |
| Glioma | EBV ZEBRA | 0.936 [0.888, 0.985] | 0.0116 |
| *IDH* mutated | EBV EBNA | 1.086 [1.004, 1.175] | 0.0402 |
| 1p/19q codeleted | EBV EBNA | 1.138 [1.012, 1.280] | 0.0308 |
| *IDH* wild type | EBV ZEBRA | 0.910 [0.850, 0.975] | 0.007 |
| MCV | 1.089 [1.018, 1.165] | 0.0131 |
| 1p/19q non-codeleted | EBV ZEBRA | 0.908 [0.844, 0.977] | 0.0099 |
| MCV | 1.11 [1.031, 1.194] | 0.0054 |

\*These results mirror those of Figure 3 in the main text

*Indentation indicates subtype is further subset of the above result*

**Table S4: Summary of GRS-glioma survival significant results\***

|  |  |  |  |
| --- | --- | --- | --- |
| **Subtype** | **Antigen GRS** | **Meta HR (95% CI)** | **Meta P-value** |
| *IDH* mutated | EBV EBNA | 0.857 [0.762, 0.964] | 0.01 |
| 1p/19q codeleted | EBV EBNA | 0.754 [0.569, 0.998] | 0.048 |
| EBV ZEBRA | 1.268 [1.009, 1.592] | 0.0415 |
| 1p/19q non-codeleted | EBV EBNA | 0.860 [0.741, 0.997] | 0.0452 |

\*These results mirror those of Figure 4 in the main text

*Indentation indicates subtype is further subset of the above result*

**Table S5: Summary of available cases and events for survival analyses**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **UCSF-Mayo** | | **TCGA** | | **AGS i370** | |
| **Molecular Subtype** | **Cases** | **Events** | **Cases** | **Events** | **Cases** | **Events** |
| Glioma | 1973 | 1218 | 786 | 310 | 659 | 592 |
| *IDH* mutated | 588 | 201 | 375 | 50 | 111 | 74 |
| 1p/19q codeleted | 244 | 64 | 143 | 13 | 9 | 1 |
| 1p/19q non-codeleted | 291 | 117 | 230 | 36 | 94 | 69 |
| *IDH* wild type | 699 | 594 | 364 | 228 | 416 | 402 |
| 1p/19q non-codeleted | 507 | 458 | 357 | 224 | 416 | 402 |

Study/subtype combinations with less than 50 cases or 20 events were not utilized in the meta-analysis of survival associations.

*Indentation indicates subtype is further subset of the above*

**Figure S1: All GRS-Glioma risk meta-result forest plots, by antigen**

**S1 A) Glioma overall**



**S1 B) *IDH* mutated**

****

**S1 C) *IDH* mutated 1p/19q codeleted**

****

**S1 D) *IDH* mutated 1p/19q non-codeleted**

****

**S1 E) *IDH* wild type**

****

**S1 F) *IDH* wild type 1p/19q non-codeleted**

****

A-F) Forest plot meta-analysis results of all tested GRS-glioma risk associations for the specific primary subtype. Results are reported as odds ratios, along with 95% confidence intervals. Briefly, each header indicates the studied glioma molecular subtype, within are each GRSs associations with the subtype, and the 95% confidence interval of each study-specific effect. The diamond visualizes the 95% confidence interval for the fixed effect (FE) meta-analysis across studies. Each meta-analysis was tested for between-study heterogeneity (Q statistic), with p<0.05 indicating evidence of study-specific associations. GRS-subtype tests with evidence of significant heterogeneity were re-analyzed using a random-effects meta-analysis (results not reported). No new suggestive associations were found after re-analysis.

**Figure S2: All GRS-Glioma survival meta result forest plots, by antigen**

**S2 A) Glioma overall**

****

**S2 B) *IDH* mutated**



**S2 C) *IDH* mutated 1p/19q codeleted**

****

**S2 D) *IDH* mutated 1p19 non-codeleted**

****

**S2 E) *IDH* wild type**

****

**S2 F) *IDH* wild type 1p/19q non-codeleted**

****

A-F) Forest plot meta-analysis results of all tested GRS-glioma survival associations. Results are reported as hazard ratios, along with 95% confidence intervals. Briefly, each header indicates the studied glioma molecular subtype, within are each GRSs associations with the clinical outcomes of that subtype, and the 95% confidence interval of each study-specific effect. The diamond visualizes the 95% confidence interval for the fixed effect (FE) meta-analysis across included studies. Studies which had an insufficient number of cases/events in a subtype were not included in the meta-analysis and no meta-analysis was performed if only one study was included. Each meta-analysis was tested for between-study heterogeneity (Q statistic), with p<0.05 indicating evidence of study-specific associations. GRS-subtype tests with evidence of significant heterogeneity were re-analyzed using a random-effects meta-analysis (results not reported). No new suggestive associations were found after re-analysis.

**Figure S3: Glioma survival Kaplan-Meier curves by antigen GRS and subtype**

**S3 A) Glioma overall**

****

**S3 B) *IDH* mutated**

****

**S3 C) *IDH* mutated 1p/19q codeleted**

****

**S3 D) *IDH* mutated 1p19 non-codeleted**

****

**S3 E) *IDH* wild type**

****

**S3 F) *IDH* wild type 1p/19q non-codeleted**

****

A-F) Kaplan-Meier curves for GRS associations with the survival in the specified molecular glioma subtype. Each plot represents a visualization of the association of a specific viral antigen GRS with clinical outcomes in the molecular subtype. To visualize, each antigen's unnormalized GRS scores across the included studies were binned based on the case-specific 80th percentile score in the UCSF-Mayo dataset. P-values included on each plot are results of a log-rank test for difference between the two curves. Below each set of curves provides the number of cases surviving beyond that time point, for each of the two GRS groups.